Lewis R Roberts

Prof. Lewis R Roberts

Mayo Clinic, Rochester, Indiana, USA
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2018 in Hepatology
Verified
Journal Article
Open access
PDF file
JMJorge A. Marrero
Jorge A. Marrero
LKLaura M. Kulik
Laura M. Kulik
CSClaude B. Sirlin
Claude B. Sirlin
AZAndrew X. Zhu
Andrew X. Zhu
RFRichard S. Finn
Richard S. Finn
JHJulie K. Heimbach
Julie K. Heimbach

22 August 2019 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
JYJu Dong Yang
Ju Dong Yang
PHPierre Hainaut
Pierre Hainaut
GGGregory J. Gores
Gregory J. Gores
AAAmina Amadou
Amina Amadou
APAmelie Plymoth
Amelie Plymoth
LRLewis R Roberts
Lewis R Roberts

28 January 2017 in Hepatology
Verified
Journal Article
Open access
PDF file
JHJulie K. Heimbach
Julie K. Heimbach
LKLaura M. Kulik
Laura M. Kulik
RFRichard S. Finn
Richard S. Finn
CSClaude B. Sirlin
Claude B. Sirlin
MAMichael M. Abecassis
Michael M. Abecassis
JMJorge A. Marrero
Jorge A. Marrero
Click on the article title to read more.

30 June 2020 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Open access
PDF file
Jesús BañalesJesús Bañales
Jesús Bañales
Jose MarinJose Marin
Jose Marin
ALAngela Lamarca
Angela Lamarca
Cecilia MP RodrigugesCecilia MP Rodriguges
Cecilia MP Rodriguges
SKShahid A Khan
Shahid A Khan
GGGregory J. Gores
Gregory J. Gores
Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for ~15% of all primary liver cancers and ~3% of gastrointestinal malignancies. The silent presentation of these tumours combined with their highly aggressive nature and refractoriness to chemotherapy contribute to their alarming mortality, representing ~2% of all cancer-related deaths worldwide yearly. The current diagnosis of CCA by non-invasive approaches is not accurate enough, and histological confirmation is necessary. Furthermore, the high heterogeneity of CCAs at the genomic, epigenetic and molecular levels severely compromises the efficacy of the available therapies. In the past decade, increasing efforts have been made to understand the complexity of these tumours and to develop new diagnostic tools and therapies that might help to improve patient outcomes. In this expert Consensus Statement, which is endorsed by the European Network for the Study of Cholangiocarcinoma, we aim to summarize and critically discuss the latest advances in CCA, mostly focusing on classification, cells of origin, genetic and epigenetic abnormalities, molecular alterations, biomarker discovery and treatments. Furthermore, the horizon of CCA for the next decade from 2020 onwards is highlighted.

1 March 2017 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
SBSarah Blach
Sarah Blach
SZStefan Zeuzem
Stefan Zeuzem
MMMichael Manns
Michael Manns
IAIbrahim Altraif
Ibrahim Altraif
ADAnn-Sofi Duberg
Ann-Sofi Duberg
HRHomie Razavi
Homie Razavi

5 March 2015 in Liver International
Verified
Journal Article
Open access
PDF file
JPJoong-Won Park
Joong-Won Park
MCMinshan Chen
Minshan Chen
MCMassimo Colombo
Massimo Colombo
LRLewis R Roberts
Lewis R Roberts
MSMyron Schwartz
Myron Schwartz
MSMorris Sherman
Morris Sherman
Background & Aims: Hepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide. The global HCC BRIDGE study was a multiregional, large‐scale, longitudinal cohort study undertaken to improve understanding of real‐life management of patients with HCC, from diagnosis to death.Methods: Data were collected retrospectively from January 2005 to September 2012 by chart reviews of eligible patients newly diagnosed with HCC at participating institutions.Results: Forty‐two sites in 14 countries contributed final data for 18 031 patients. Asia accounted for 67% of patients, Europe for 20% and North America for 13%. As expected, the most common risk factor was hepatitis C virus in North America, Europe and Japan, and hepatitis B virus in China, South Korea and Taiwan. The most common Barcelona Clinic Liver Cancer stage at diagnosis was C in North America, Europe, China and South Korea, and A in Taiwan and Japan. Across all stages, first HCC treatment was most frequently transarterial chemoembolization in North America, Europe, China and South Korea, percutaneous ethanol injection or radiofrequency ablation in Japan and resection in Taiwan. Survival from first HCC treatment varied significantly by region, with median overall survival not reached for Taiwan and 60, 33, 31, 24 and 23 months for Japan, North America, South Korea, Europe and China respectively (P < 0.0001).Conclusions: Initial results from the BRIDGE study confirm previously reported regional trends in patient demographic characteristics and HCC risk factors, document the heterogeneity of treatment approaches across regions/countries and underscore the need for earlier HCC diagnosis worldwide.